World Class Leading Brand of HPMC
METHOCEL™ cellulose ethers are water-soluble polymers derived from cellulose, which is a renewable raw material mainly from wood pulp and sourced primarily from suppliers with certified sustainable forestry practices.
The METHOCEL™ product family offers exceptional flexibility and a combination of properties typically not found in other water-soluble polymers. There are two polymer types – methylcellulose and hydroxypropyl methylcellulose –– available as various grades covering a wide range of viscosities and or substitution grades, powder properties and chemical design.
The products have been successfully used for over 70 years in a number of pharmaceutical applications including: controlled or modified release formulations, dry processes, granulation and binding, tablet coating, liquid solutions or suspensions and topical creams.
Applications for METHOCEL™ Polymers
METHOCEL™ polymers are designed to offer consistent drug release performance. API release can be modified depending on the choice of substitution and viscosity grade of METHOCEL utilized in the formulation.
METHOCEL™ products offer thin glossy coating that can be printed upon, are non-tacky, compatible with pigments and dyes, are easily swallowed, and are hypo-allergenic. In addition, METHOCEL™ VLV Premium tablet coatings are designed to minimize coating time.
METHOCEL™ products are used in topical liquid formulations because they are excellent thickeners (rheology modifiers), improve emulsion stability, suspend solids, lubricate and retain moisture.
The protective colloid action and emulsifying properties of METHOCEL™ benefit many semi-solid formulations. METHOCEL™ can also contribute film-forming and thickening properties which improve after-feel and other sensory characteristics in creams and lotions.
METHOCEL™ products can be used as thickeners, binders, film-formers and for water-retention in a number of pharmaceutical applications. METHOCEL™ products stabilize liquid suspensions.
METHOCEL™ DC2 excipients are engineered to facilitate dry powder flow, thus improving reproducibility of tablet properties produced using dry powder processing techniques, such as direct compression and dry granulation. METHOCEL™ DC2 excipients streamline matrix tablet manufacture, deliver modified-release performance, and facilitate processing of heat- and moisture-sensitive APIs.
METHOCEL™ DC2 helps shorten product development time and reduce manufacturing costs by up to 60% while enabling up to 15% higher press operation speed.
METHOCEL™ Premium LV products offer binding and adhesive properties as well as excellent tablet hardness without increasing friability or impacting API release during the granulation process for immediate-release tablets.
With low concentrations, METHOCEL™ Premium LV can also reduce the required compression forces necessary to process wet-granulated intermediates, resulting in less wear and tear on equipment. The minimal concentrations needed, facilitate smaller tablet size and allow the use of additional excipients necessary to control other tablet properties.
Nasal DeliveryMETHOCEL™ Cellulose Ethers have unique capabilities to control solution viscosity, direct drug spray pattern and retain drug on the mucosa to allow for permeation. These are key requirements for the deposition and delivery of small molecules & biologics.
Dow has been a leading provider of METHOCEL™ HPMC based solutions to capsule producers for over a decade. Dow works closely with their customer partners to find the best METHOCEL™ solution for their capsule needs, helping them address emerging trends and working with them to optimize their end product performance and total cost of ownership.